AnaptysBio, Inc. (ANAB)
56.18
-1.11
(-1.94%)
USD |
NASDAQ |
Aug 28, 16:00
56.18
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Enterprise Value : 1.654B for Aug. 27, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 1.654B |
| August 26, 2026 | 1.675B |
| August 25, 2026 | 1.685B |
| August 24, 2026 | 1.687B |
| August 21, 2026 | 1.667B |
| August 20, 2026 | 1.637B |
| August 19, 2026 | 1.711B |
| August 18, 2026 | 1.703B |
| August 17, 2026 | 1.724B |
| August 14, 2026 | 1.688B |
| August 13, 2026 | 1.617B |
| August 12, 2026 | 1.645B |
| August 11, 2026 | 1.671B |
| August 10, 2026 | 1.601B |
| August 07, 2026 | 1.634B |
| August 06, 2026 | 1.581B |
| August 05, 2026 | 1.587B |
| August 04, 2026 | 1.591B |
| August 03, 2026 | 1.549B |
| July 31, 2026 | 1.540B |
| July 30, 2026 | 1.589B |
| July 29, 2026 | 1.505B |
| July 28, 2026 | 1.504B |
| July 27, 2026 | 1.547B |
| July 24, 2026 | 1.563B |
| Date | Value |
|---|---|
| July 23, 2026 | 1.585B |
| July 22, 2026 | 1.518B |
| July 21, 2026 | 1.552B |
| July 20, 2026 | 1.451B |
| July 17, 2026 | 1.675B |
| July 16, 2026 | 1.563B |
| July 15, 2026 | 1.611B |
| July 14, 2026 | 1.806B |
| July 13, 2026 | 2.018B |
| July 10, 2026 | 1.918B |
| July 09, 2026 | 1.924B |
| July 08, 2026 | 1.888B |
| July 07, 2026 | 1.945B |
| July 06, 2026 | 1.800B |
| July 02, 2026 | 1.832B |
| July 01, 2026 | 1.890B |
| June 30, 2026 | 1.950B |
| June 29, 2026 | 1.906B |
| June 26, 2026 | 1.824B |
| June 25, 2026 | 1.723B |
| June 24, 2026 | 1.689B |
| June 23, 2026 | 1.716B |
| June 22, 2026 | 1.732B |
| June 18, 2026 | 1.660B |
| June 17, 2026 | 1.639B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| 4D Molecular Therapeutics, Inc. | 501.13M |
| Design Therapeutics, Inc. | 749.61M |
| Inhibrx Biosciences, Inc. | 1.871B |
| Agenus, Inc. | 597.49M |
| Amgen, Inc. | 279.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.88M |
| Revenue (Quarterly) | 25.56M |
| Total Expenses (Quarterly) | 78.44M |
| EPS Diluted (Quarterly) | -1.843 |
| Gross Profit Margin (Quarterly) | 97.61% |
| Profit Margin (Quarterly) | -206.9% |
| Earnings Yield | -1.92% |
| Operating Earnings Yield | 2.46% |
| Normalized Earnings Yield | -1.923 |